Hormone implant aimed at saving uteruses after failed ablation – trial pulled
NCT ID NCT05227456
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study planned to test whether an etonogestrel implant (Nexplanon) could reduce the need for hysterectomy in women who still had abnormal bleeding or pelvic pain after endometrial ablation. The trial was withdrawn before enrolling any participants, so no data were collected. The implant releases a hormone to control bleeding and pain, but its effectiveness in this specific situation remains unknown.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
etonogestrel implant (Nexplanon)
What this could lead to
If it had worked, this could have offered a way to avoid hysterectomy for women with continued bleeding or pain after endometrial ablation.
What could go wrong
The trial was withdrawn before enrolling any participants, so no results are available. Etonogestrel implants can cause side effects like irregular bleeding, mood changes, or weight gain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ABNORMAL UTERINE BLEEDING are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Saskatchewan Health Authority
Regina, Saskatchewan, Canada